Nonalcoholic Fatty Liver Disease Diagnosis

Nonalcoholic fatty liver disease (NAFLD) is often found incidentally through routine blood work or imaging. In collaboration with our Pathology Department and Radiology Department, our liver disease experts can confirm a diagnosis of NAFLD with the following tests:

  • Blood tests
  • Ultrasound
  • CT scan or MRI
  • Fibroscan
  • Liver biopsy

Treatment

Currently, there is no Food and Drug Administration (FDA) approved medication for the treatment of NAFLD. This does not mean, however, that there is no hope for patients with fatty liver.

At Mount Sinai, we offer a multidisciplinary approach to treat NAFLD, which targets the risk factors associated with the disease such as diabetes, high cholesterol and high blood pressure. In collaboration with Primary Care and the Diabetes Center, our experts control the disease by helping patients lose weight and by introducing an exercise plan and dietary modifications.

In addition, our experts will provide tips to patients to minimize the effects of the disease, including:

  • Liming the intake of saturated fats and trans fats
  • Avoiding high fructose syrup containing foods
  • Keeping the components of metabolic syndrome under control

Advanced Nonalcoholic Fatty Liver Disease Treatment

If the disease has progressed to cirrhosis and liver cancer, our liver specialists have the resources to treat these conditions. We provide referrals to the Recanati/Miller Transplantation Institute for liver transplantation in cases of end-stage liver disease as well as to Interventional Radiology and Surgical Oncology to treat any associated liver cancer.

Mount Sinai has an active research interest which allows us to offer clinical trials to selected patients. Currently, we offer the following clinical trials:

  • A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH) – This study focuses on treatment of fatty liver disease with the use of an insulin sensitizing agent.
  • A Phase 2B, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trail Evaluating the Safety and Efficacy of GS-6624 Against LOXL2, in Patients with Aadvanced Liver Fibrosis but not Cirrhosis Secondary to NASH – This clinical trial is studying the use of an agent to reverse liver scarring in patients with NASH who do not have cirrhosis
  • A Phase 2B, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trail Evaluating the Safety and Efficacy of GS-6624 Against LOXL2, in Patients with Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis – This clinical trial is studying the use of an agent to reverse liver scarring in patients with NASH who have cirrhosis

Contact Us

Tel: 212-241-0034

5 East 98th Street
12th Floor
New York, NY 10029